The risk of PD-L1 expression misclassification in triple-negative breast cancer

PURPOSE: Stratification of patients with triple-negative breast cancer (TNBC) for anti-PD-L1 therapy is based on PD-L1 expression in tumor biopsies. This study sought to evaluate the risk of PD-L1 misclassification. METHODS: We conducted a high-resolution analysis on ten surgical specimens of TNBC....

Descripción completa

Detalles Bibliográficos
Autores principales: Ben Dori, Shani, Aizic, Asaf, Zubkov, Asia, Tsuriel, Shlomo, Sabo, Edmond, Hershkovitz, Dov
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2022
Materias:
Clinical Trial
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9239943/
https://www.ncbi.nlm.nih.gov/pubmed/35622241
http://dx.doi.org/10.1007/s10549-022-06630-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9239943/
https://www.ncbi.nlm.nih.gov/pubmed/35622241
http://dx.doi.org/10.1007/s10549-022-06630-3

Ejemplares similares